ADMA Biologics Inc (ADMA)

NASDAQ
1.79
-0.01(-0.56%)
After Hours
1.79
0.00(0.00%)
- Real-time Data
  • Volume:
    1,530,626
  • Bid/Ask:
    1.75/1.82
  • Day's Range:
    1.77 - 1.83

ADMA Overview

Prev. Close
1.8
Day's Range
1.77-1.83
Revenue
48.08M
Open
1.8
52 wk Range
1.45-4.18
EPS
-0.79
Volume
1,530,626
Market Cap
229.46M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
6,949,373
P/E Ratio
-
Beta
1.3
1-Year Change
-41.75%
Shares Outstanding
128,189,628
Next Earnings Date
Aug 06, 2021
What is your sentiment on ADMA Biologics Inc?
or
Market is currently closed. Voting is open during market hours.

ADMA Biologics Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuySellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyNeutralBuyStrong Sell
SummaryBuyNeutralNeutralNeutralStrong Sell

ADMA Biologics Inc Company Profile

ADMA Biologics Inc Company Profile

Employees
406

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics. Its segments include Plasma Collection Centers, which includes its operations in Georgia; Research and Development, which includes its plasma development operations in New Jersey, and Corporate. Its targeted patient populations are immune-compromised individuals suffering from an underlying immune deficiency disorder or may be immune-suppressed for medical reasons. Its product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients at risk of contracting infectious diseases. Its intravenous immunoglobulin product candidate, RI-002, is intended for the treatment of primary immune deficiency disease.

Read More
  • 03/05/2021 13:01 - RSFU.S. RESEARCH ROUNDUP-Federated Hermes, Fidelity National Financial, JetBlue AirwaysMay 3 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Federated Hermes, Fidelity National Financial and JetBlue Airways, on Monday.....................Adma Biologics Inc : H.C. Wainwright cuts target price to $10 from $11
    0
    • Gaureentee $5 Very Sooon!!! 💰 FDA approval!
      0
      • If you draw anything on its monthly chart, it's going to be a penny stock soon. GLTA
        3
        • Skip7 hours ago I see a lot of people asking how this stock can go down on what seems to be good progress on the revenue and expansion front. Do your homework. Post
          1
          • With the issuance last year (Feb '20 offering) of 27MM common shares combined with the total open market agreement sales (Jefferies) in 2020 of an additional 18.5MM shares plus the 2021 year to date issuance of 16MM shares (Jefferies), this company is dangerously close to maxing out its authorized common shares of 150MM.
            0
          • If they have to seek approval from shareholders to authorize more common shares, or issue "blank check" preferred with no shareholder vote required...dilution will continue to keep this stock headed down...so don't count on any "short squeeze" as a rescue to your long position. I don't have anything negative to say about ADMA's business or management; you just need to look at the capital structure and understand the forces that may be working against you on the long side. Stay safe, be well.
            1
          • Just posted above comments from yahoo ADMA board, and I totally agree with above honest opinions.
            0
        • what? diluted more?! Grossman is insane! we could see it going to $1 soon
          0
          • If it is below $1 and stays, would be pleased to see the reverse split...10X, or 20X... Good luck everyone on the boat!
            0
          • Anyone can tell if Raymond James PT $6 is the price after reverse-split, or not?
            0
        • Executed Commercially with Significant Year-Over-Year Revenue Growth. Achieved full year 2020 total revenues of $42.2 million, compared to $29.3 million for the full year 2019, reflecting a substantial 44% increase. Achieved fourth quarter 2020 total revenues of $14.0 million, compared to $12.0 million for the fourth quarter of 2019, representing an approximately 16% increase.
          1
          • double down at 1.85 1.5 and $1
            0
            • double-down no more, will exit from time to time
              0
          • bought some at $2 good deal!
            0
            • Efficiency 0.5 out of 5 stars Measures the strength and historic growth of a company's return on invested capital. The company ranks at the bottom of companies we review for income generated per dollar of capital.
              0
              • While ADMA management team pocketed millions of dollars - what a ridiculous company! Short any spike!
                0
            • Any comments to yesterday's Jeffery's virtual conference? Grossman mentioned their earning date is end of this month.
              0
              • Their total shares suddenly increased from ~54M to 94M shares? Hopefully the price tomorrow won't tank too much.
                0
                • So strong performance wise, as of today 08-Feb-2021, it will shoot to the moon in coming months. Let's hold and enjoy!!!
                  0
                • The shorts will start to cover tomorrow, and the squeeze would be painful, man!!!!!!!!
                  0
              • im holding lets go
                0
                • let's buy and hold! Kick the shorters away and shooot to the mooon
                  0
                  • Such a hidden gem
                    0
                    • Who can call on WSB ret{ards to load? Then we will fly to the moon!!
                      1
                      • He comes the BOOM BUCKLE YOU LR SEATBELTS FOLKS OTS ONLY GETTING BETTER FROM HERE
                        0
                        • TP 3,70
                          0
                          • $370.00....
                            0
                          • hold tight!
                            0
                        • Dip Dip Dip
                          0
                          • Bought today 10.000 shares at 1.97$
                            0
                            • Nice Now Hold
                              0
                          • Got in Today lets go to 12$
                            0
                            • It will bro just got to be patient
                              1
                            • Chris Jones True see what happens. When you think it will rise some?
                              0
                            • stu hfADMA will be a key player in this COVID fight, this will be a long term play. So im goikg long, but also do you Due Diligence as well....
                              0
                          • Another Good day, up 10% To the moon and beyond . Lets go!!!
                            0
                            • Good Day today!!!!
                              0
                              • Going long on this one
                                0
                                • There has been talks over buying out this company since its released its latest technology last week. As you can see the price has skyrocketed during the last couple of trading days. Definitely a good buy considering the shares are already trading at a very good value + shares are apparently going to be worth up to 16$ / each if bought out
                                  0
                                  • Good long term
                                    0
                                    • How long you think?
                                      0
                                  Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                  Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.